生物医药成果卖出后 又成为高价进口药 BD交易带来隐忧

Core Viewpoint - The focus of the discussion is on the concerns raised by society and the government regarding the hidden issues associated with BD transactions, particularly the lack of globally valued multinational pharmaceutical companies [1] Group 1 - The event took place on October 14 at the 2025 Zhangjiang Pharmaceutical Valley Industry Ecosystem Global Promotion Conference [1] - Zhu Yi, the founder, chairman, and chief scientific officer of Baillie Tianheng, highlighted the attention from society and government towards the issues arising from BD transactions [1] - The primary concern is identified as the absence of multinational pharmaceutical companies that hold global value [1]